Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.
Key facts
- Where
- Thessaloniki, GörögországSee the 2 sites
- Phase
- 4. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Görögország
- Papageorgiou HospitalThessaloniki, GörögországToborzás még nem indult
- University General Hospital of Thessaloniki - AHEPAThessaloniki, GörögországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aristotle University Of Thessaloniki
- Trial code
- EU 2025-521910-24-00
- Record updated
- 2026. július 3.
- Original description
The primary endpoint is to assess changes in the immune synapse molecules in naive MS patients treated with cladribine tablets compared to healthy volunteers, at 12-months of treatment.Read full original descriptionShow less
The primary endpoint is to assess changes in the immune synapse molecules in naive MS patients treated with cladribine tablets compared to healthy volunteers, at 12-months of treatment.
Inclusion: Patients with RRMS, age ≥18 and ≤50 years old; Treatment naive; Cladribine prescription per the decision of the treating physician and according to the approved MAVENCLAD SmPC in Greece; Absence of other neurological disease; Willingness / ability to provide written informed consent; Full diagnostic workup for MS in the previous 6 months prior to the inclusion to the study.
Exclusion: Concurrent participation in an investigational study in which patient assessment and/or treatment may be dictated by a protocol; Prior or current use of other DMT; MS diagnosis >6 months prior to the inclusion to the study; Patients with history of alcohol or drug abuse that could potentially interfere with their participation in the study; Age <18 or >50; Contraindications to use of cladribine tablets according to the Summary of Product Characteristics; Evidence of progressive MS.